Cargando…

Severe Esophagitis and Gastritis from Nivolumab Therapy

Nivolumab is a novel chemotherapy currently approved for the treatment of multiple metastatic malignancies. This class of therapy, known as immune checkpoint inhibitors, is notable for an autoimmune-related adverse event profile. Diarrhea and colitis are common gastrointestinal adverse events, howev...

Descripción completa

Detalles Bibliográficos
Autores principales: Boike, Justin, Dejulio, Todd
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American College of Gastroenterology 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5404341/
https://www.ncbi.nlm.nih.gov/pubmed/28459081
http://dx.doi.org/10.14309/crj.2017.57